Economic Evaluation Of Paliperidone Palmitate Use In Patients With Schizophrenia In The Maintenance Phase (Post-Relapse Or Stabilization) In Colombia

Keyphrases

• Colombia 100%
• Paliperidone Palmitate 100%
• Economic Evaluation 100%
• Risperidone Long-acting Injection 100%
• Maintenance Phase 100%
• Patients with Schizophrenia 100%
• Olanzapine 80%
• Quetiapine 80%
• Risperidone 80%
• Quality-adjusted Life Years 60%
• Incremental Cost-effectiveness Ratio 60%
• Paliperidone Palmitate Long-acting Injection 60%
• Antipsychotics 40%
• Expected Cost 40%
• Hospitalization 20%
• Relapse Prevention 20%
• Schizophrenia 20%
• Medical Monitoring 20%
• Advisory Board 20%
• Sensitivity Analysis 20%
• Direct Medical Costs 20%
• Cost-effectiveness Analysis 20%
• Markov Model 20%
• Schizophrenia Treatment 20%
• Treatment Phase 20%
• Medical Experts 20%
• Usage Patterns 20%
• Third-party Payers 20%
• Relapse Risk 20%
• Average Length of Stay 20%
• Mental Hospital 20%
• Antipsychotic Treatment 20%
• Cost of Care 20%
• Subsequent Therapy 20%
• Therapist Support 20%
• Therapy Monitoring 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Paliperidone 100%
• Risperidone 100%
• Schizophrenia 100%
• Olanzapine 44%
• Quetiapine 44%
• Antipsychotic 11%